Enterprise Value to EBITDA Ratio: TuHURA (HURA)
TuHURA Biosciences, Inc. (HURA) coordinates the precise international transport of tumor therapy components, utilizing a network of hubs to protect margins. This market valuation chart on GURU.Markets demonstrates the 0.00 metric. Physicians value TuHURA Biosciences, Inc. (HURA) for its breakthrough vaccines, which secures investor confidence. Business stability relies on US centers developing drugs to prevent disease recurrence.
Analytical breakdowns for TuHURA (HURA)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio TuHURA Biosciences, Inc.|HURA - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio TuHURA Biosciences Inc.|HURA - Company Aggregate Debts|Debts to Book Capitalization TuHURA Biosciences Inc.|HURA - Company Long-Term Loans and Borrowings|Company Current Liabilities TuHURA Biosciences|Quick Liquidity tuhurabio.com
- business earnings and investment ratios data:
HURA - Final Profit|Projected Future Earnings TuHURA Biosciences, Inc.|HURA - P/E Multiple|Projected Price to Earnings TuHURA Biosciences, Inc.|HURA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple TuHURA Biosciences, Inc.|HURA - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) TuHURA Biosciences|HURA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months tuhurabio.com|HURA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year TuHURA Biosciences, Inc.
- company sales and revenue statistics:
Fundamental company analysis:TuHURA Biosciences HURA
Defensive portfolio screening requires an analysis of how capital-intensive structures withstand debt loads. This metric compares the total enterprise value of a business with its operating profit before depreciation and amortization to determine the payback period of assets. For TuHURA Biosciences, Inc. (HURA), this calculation reflects the value of intellectual property relative to the efficiency of anti-cancer vaccine development. The rising EV/EBITDA ratio for TuHURA Biosciences, Inc. (HURA) signals that market expectations are overextended relative to the actual commercial potential of the technologies.
Key competitors
BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple
